# Seborrhoeic dermatitis of the scalp
**Seborrhoeic dermatitis of the scalp** is a chronic, relapsing inflammatory skin disease of the scalp characterized by varying degrees of scaling, inflammation, exudation, and crusting; it may occur alone or with seborrhoeic dermatitis at other sites, and dandruff (pityriasis capitis) is considered its mild, uninflamed form.[1](https://www.findacode.com/icd-11/code-1010943819.html) In the WHO's ICD-11 classification it carries the code EA81.1, with synonyms including seborrhoeic eczema of scalp, pityriasis capitis, and dandruff.[1](https://www.findacode.com/icd-11/code-1010943819.html)
| Key fact | Detail |
|---|---|
| Definition | Chronic, relapsing inflammatory scalp disease with scaling, inflammation, exudation, and crusting; dandruff is its mild form[1](https://www.findacode.com/icd-11/code-1010943819.html) |
| Global prevalence of seborrhoeic dermatitis | Pooled 4.38% (95% CI 3.58–5.17%); adults 5.64%, children 3.70%, neonates 0.23%[2](https://jamanetwork.com/journals/jamadermatology/fullarticle/2820685) |
| Spectrum burden | SD and dandruff together affect an estimated half of the adult population; at least 50 million Americans are thought to be affected, with $300 million spent annually on over-the-counter products[3](https://onlinelibrary.wiley.com/doi/full/10.1111/exd.14091) |
| Main microbial association | *Malassezia* yeasts, with *M. restricta* predominating on the scalp and forehead[4](https://pmc.ncbi.nlm.nih.gov/articles/PMC12562114/) |
| First-line treatment | Medicated shampoos containing ketoconazole, ciclopirox, selenium sulfide, zinc pyrithione, coal tar, or salicylic acid, used twice weekly for at least a month[5](https://dermnetnz.org/topics/seborrhoeic-dermatitis) |
| Evidence for antifungals | Ketoconazole reduced failed clearance versus placebo (RR 0.69, 95% CI 0.59–0.81); ciclopirox 1% similarly (RR 0.79, 95% CI 0.67–0.94)[6](https://www.cochrane.org/evidence/CD008138_antifungal-treatments-applied-skin-treat-seborrhoeic-dermatitis) |
| Age distribution | Bimodal: a peak in infancy (2–12 months) and another in early adulthood[3](https://onlinelibrary.wiley.com/doi/full/10.1111/exd.14091) |
## Clinical features and course
The condition presents as ill-defined erythematous, scaly patches with greasy or yellowish scaling on the scalp, in a chronic and relapsing course.[4](https://pmc.ncbi.nlm.nih.gov/articles/PMC12562114/) Dandruff, the mildest end of the spectrum, is restricted to the scalp and involves itchy, flaking skin without visible inflammation.[7](https://pmc.ncbi.nlm.nih.gov/articles/PMC4852869) Winter flares with improvement after summer sun exposure are typical, and itch is minimal most of the time.[5](https://dermnetnz.org/topics/seborrhoeic-dermatitis)
In adults the condition is frequently chronic, and long-term maintenance treatment is often necessary.[5](https://dermnetnz.org/topics/seborrhoeic-dermatitis) Untreated scalp inflammation carries a risk of skin damage or hair loss, according to Adam Friedman, a dermatologist and researcher commenting on scalp disease.[8](https://time.com/3721947/itchy-scalp-dandruff-causes/)
## Epidemiology
A 2024 systematic review and meta-analysis of 121 studies covering 1,260,163 individuals found a pooled global seborrhoeic dermatitis prevalence of 4.38% (95% CI, 3.58–5.17%), with substantial heterogeneity. Prevalence was higher in adults (5.64%) than in children (3.70%) and lowest in neonates (0.23%). By country, the highest reported prevalence was in South Africa (8.82%) and the lowest in India (2.62%).[2](https://jamanetwork.com/journals/jamadermatology/fullarticle/2820685) This pooled figure exceeds the 2019 Global Burden of Disease estimate of 0.29%, a gap the authors attribute to undercoding of a condition often perceived as mild.[2](https://jamanetwork.com/journals/jamadermatology/fullarticle/2820685)
Severity clusters in specific populations. The incidence is higher among HIV-infected and immunocompromised patients, ranging from 30% to 83%.[3](https://onlinelibrary.wiley.com/doi/full/10.1111/exd.14091) In patients with [Parkinson's disease](https://www.edgepedia.org/parkinsons-disease), prevalence ranges from 52% to 59%, with seborrhoeic dermatitis reported in over half of cases.[4](https://pmc.ncbi.nlm.nih.gov/articles/PMC12562114/) Susceptibility is also shaped by gender, individual lipid composition, immune status, neuropsychiatric factors, and high environmental humidity and heat.[3](https://onlinelibrary.wiley.com/doi/full/10.1111/exd.14091)
## Pathophysiology
Current understanding rests on three major pillars: alteration of the skin microbiome, dysfunction of sebaceous gland secretion, and the host immune response, with genetic predisposition a possible fourth factor whose clinical relevance is not yet fully established.[4](https://pmc.ncbi.nlm.nih.gov/articles/PMC12562114/) The immune response involves Th1, Th17, Th2, and Th22 pathways, alongside epidermal barrier dysfunction.[4](https://pmc.ncbi.nlm.nih.gov/articles/PMC12562114/)
**The yeast question.** *Malassezia*, a genus of more than 14 lipophilic yeast species, has been associated with dandruff and seborrhoeic dermatitis since the fungi were first described; the original evidence was the organisms' presence in high numbers on affected skin and the response of both conditions to treatments that inhibit or destroy them.[9](https://pubmed.ncbi.nlm.nih.gov/21919896/) *M. globosa* and *M. restricta* are the species most frequently associated with the disease, and *M. restricta* predominates on the scalp and forehead.[4](https://pmc.ncbi.nlm.nih.gov/articles/PMC12562114/) The yeast's lipases and phosphatases hydrolyze sebaceous lipids, and because it preferentially consumes saturated fatty acids, unsaturated fatty acids such as oleic acid are left behind; oleic acid penetrates the stratum corneum, promotes inflammation, and induces desquamation, exacerbating flaking.[4](https://pmc.ncbi.nlm.nih.gov/articles/PMC12562114/) Genomic and proteomic tools have identified specific phospholipases produced on affected skin in dandruff and signaling molecules such as malassezin in seborrhoeic dermatitis.[9](https://pubmed.ncbi.nlm.nih.gov/21919896/)
The correlation between fungal load and disease severity, however, remains controversial.[4](https://pmc.ncbi.nlm.nih.gov/articles/PMC12562114/) Bacteria participate as well: patients with scalp seborrheic dermatitis harbor higher levels of *Staphylococcus* spp. and *M. restricta* than healthy controls, who instead show higher levels of *Propionibacterium* spp. and *M. globosa*, and the imbalance between fungal and bacterial communities appears to be a key driver of disease.[4](https://pmc.ncbi.nlm.nih.gov/articles/PMC12562114/)
## Diagnosis
Diagnosis is clinical, based on the location and appearance of lesions; no disease-specific biomarkers have been identified.[4](https://pmc.ncbi.nlm.nih.gov/articles/PMC12562114/) [Skin biopsy](https://www.edgepedia.org/skin-biopsy) is not routinely recommended but may be considered in atypical or treatment-resistant cases or to distinguish the condition from psoriasis, lupus erythematosus, or atopic dermatitis.[4](https://pmc.ncbi.nlm.nih.gov/articles/PMC12562114/) [Histopathology](https://www.edgepedia.org/histopathology) shows a spongiotic dermatitis with the classical evolution of the other eczemas; infundibular ostia parakeratosis is frequent, and the chronic phase shows more psoriasiform hyperplasia.[10](https://pmc.ncbi.nlm.nih.gov/articles/PMC10264915/)
**Trichoscopy** (dermoscopy of hair and scalp) supports the diagnosis: the main findings are arborizing vessels and yellowish scales, with newer described signs including the dandelion vascular conglomerate, a "cherry blossom" vascular pattern, and intrafollicular oily material.[10](https://pmc.ncbi.nlm.nih.gov/articles/PMC10264915/)
The main differential diagnoses are dandruff (pityriasis sicca), scalp psoriasis, sebopsoriasis, and tinea capitis.[10](https://pmc.ncbi.nlm.nih.gov/articles/PMC10264915/) [Scalp psoriasis](https://www.edgepedia.org/scalp-psoriasis) is the most important: it shows demarcated thick plaques with silvery scale, and on biopsy reveals hypogranulosis, confluent parakeratosis, and neutrophils at the corneal layer.[10](https://pmc.ncbi.nlm.nih.gov/articles/PMC10264915/) [Tinea capitis](https://www.edgepedia.org/tinea-capitis) shows scaly, red, slightly raised patches with central clearing, and trichoscopy may show broken, corkscrew, and "zig-zag" hairs; a mycological exam can be requested in some cases.[10](https://pmc.ncbi.nlm.nih.gov/articles/PMC10264915/)
## Treatment
Treatment does not cure the disease but relieves symptoms; the goals are to clear or lessen the rash and scales, ease itch and swelling, and prevent flare-ups.[11](https://www.cochrane.org/evidence/CD009446_topical-anti-inflammatory-agents-seborrhoeic-dermatitis-face-or-scalp) • [12](https://www.aad.org/public/diseases/a-z/seborrheic-dermatitis-treatment) [Scalp](https://www.edgepedia.org/scalp) disease is most conveniently treated with shampoos containing antifungal agents, corticosteroids, or keratolytic agents, including combination products.[13](https://pmc.ncbi.nlm.nih.gov/articles/PMC3579488/) According to DermNet's treatment guidance, scalp care can involve shampoo formulations with active ingredients such as ketoconazole, [ciclopirox](https://www.edgepedia.org/ciclopirox), selenium sulfide, zinc pyrithione, coal tar, or salicylic acid, applied two times per week for a minimum of one month and, where needed, on an ongoing basis; itchy skin may be treated with steroid preparations for the scalp, while tacrolimus and other calcineurin inhibitors offer an option in place of steroids.[5](https://dermnetnz.org/topics/seborrhoeic-dermatitis)
**Trial evidence.** A Cochrane review of 51 studies with 9,052 participants found that topical ketoconazole 2% reduced the risk of failed clearance versus placebo by 31% (RR 0.69, 95% CI 0.59–0.81, low-quality evidence), while ciclopirox 1% also beat placebo (RR 0.79, 95% CI 0.67–0.94, moderate-quality evidence); ketoconazole and ciclopirox performed similarly against each other (RR 1.09, 95% CI 0.95–1.26). Ketoconazole achieved remission rates similar to steroids (RR 1.17) with 44% fewer side effects (RR 0.56, moderate-quality evidence).[6](https://www.cochrane.org/evidence/CD008138_antifungal-treatments-applied-skin-treat-seborrhoeic-dermatitis) In a randomized, double-blind trial of 350 patients with scalp seborrhoeic dermatitis, 1.5% ciclopirox olamine shampoo reduced the affected scalp area by a mean 48.2 cm² versus 41.4 cm² for 2% ketoconazole shampoo and 20.0 cm² for placebo, and patients rated ciclopirox superior to placebo (p<0.001) and to ketoconazole (p<0.05) on overall signs and symptoms.[14](https://pubmed.ncbi.nlm.nih.gov/17520465/) A BMJ Clinical Evidence review concluded that ciclopirox 1% twice weekly is a reasonable alternative to ketoconazole for clearance and maintenance, with local skin irritation as the main adverse effect.[15](https://pmc.ncbi.nlm.nih.gov/articles/PMC4445675/)
**Steroids and newer agents.** In short-term trials of four weeks or less, topical steroids achieved total clearance more often than placebo (RR 3.76, 95% CI 1.22–11.56, three RCTs, 313 participants).[11](https://www.cochrane.org/evidence/CD009446_topical-anti-inflammatory-agents-seborrhoeic-dermatitis-face-or-scalp) [Roflumilast](https://www.edgepedia.org/roflumilast) 0.3% foam, a topical PDE4 inhibitor, has received FDA approval for seborrhoeic dermatitis in patients aged 9 years and older; in a clinical trial, 68.3% of patients had clear or almost clear skin within 8 weeks.[12](https://www.aad.org/public/diseases/a-z/seborrheic-dermatitis-treatment) • [5](https://dermnetnz.org/topics/seborrhoeic-dermatitis) For resistant adult cases, oral itraconazole, tetracycline antibiotics, phototherapy, or low-dose oral isotretinoin may be recommended.[5](https://dermnetnz.org/topics/seborrhoeic-dermatitis)
## Reframing the role of Malassezia
A 2024 review in *Journal der Deutschen Dermatologischen Gesellschaft* argues that the popular yeast-centered hypothesis should be reevaluated: many findings supporting a primary causative role for *Malassezia*, including yeast proliferation on lesional skin and empiric response to antifungal therapy, have not been reproducible or consistent, and data from targeted anti-inflammatory therapeutics, genome-wide association studies, and murine models support reframing seborrhoeic dermatitis as based primarily on dysregulation of the host immune system and epidermal barrier, like other eczemas.[16](https://pubmed.ncbi.nlm.nih.gov/38472524/) This position extends an argument first made by Tania C. Wikramanayake and colleagues, researchers in dermatology, in a 2019 Experimental Dermatology perspective, which noted that high *Malassezia* counts and antifungal responsiveness coexist with strong challenges to a yeast-centric view.[17](https://onlinelibrary.wiley.com/doi/10.1111/exd.14006) An international expert consensus published in 2024 on managing adult scalp seborrhoeic dermatitis nonetheless retains topical antifungals and anti-inflammatory agents as the mainstay of current treatment.[18](https://pubmed.ncbi.nlm.nih.gov/38919137/)
## References
1. [EA81.1 Seborrhoeic dermatitis of the scalp, ICD-11 MMS](https://www.findacode.com/icd-11/code-1010943819.html)
2. [The Global Prevalence of Seborrheic Dermatitis: A Systematic Review and Meta-Analysis, JAMA Dermatology (2024)](https://jamanetwork.com/journals/jamadermatology/fullarticle/2820685)
3. [Adalsteinsson et al. (2020). An update on the microbiology, immunology and genetics of seborrheic dermatitis. Experimental Dermatology](https://onlinelibrary.wiley.com/doi/full/10.1111/exd.14091)
4. [Seborrheic Dermatitis Revisited: Pathophysiology, Diagnosis, and Emerging Therapies—A Narrative Review, PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC12562114/)
5. [Seborrhoeic dermatitis: Causes and treatment, DermNet](https://dermnetnz.org/topics/seborrhoeic-dermatitis)
6. [Antifungal treatments applied to the skin to treat seborrhoeic dermatitis, Cochrane Database of Systematic Reviews 2015](https://www.cochrane.org/evidence/CD008138_antifungal-treatments-applied-skin-treat-seborrhoeic-dermatitis)
7. [Seborrheic Dermatitis and Dandruff: A Comprehensive Review, PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC4852869)
8. [You Asked: Why Is My Scalp So Itchy?, TIME](https://time.com/3721947/itchy-scalp-dandruff-causes/)
9. [Hay RJ (2011). Malassezia, dandruff and seborrhoeic dermatitis: an overview. British Journal of Dermatology](https://pubmed.ncbi.nlm.nih.gov/21919896/)
10. [Scalp Seborrheic Dermatitis: What We Know So Far, PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC10264915/)
11. [Topical anti-inflammatory agents for seborrhoeic dermatitis of the face or scalp, Cochrane Database of Systematic Reviews 2014](https://www.cochrane.org/evidence/CD009446_topical-anti-inflammatory-agents-seborrhoeic-dermatitis-face-or-scalp)
12. [Seborrheic dermatitis: Diagnosis and treatment, American Academy of Dermatology](https://www.aad.org/public/diseases/a-z/seborrheic-dermatitis-treatment)
13. [Optimizing Treatment Approaches in Seborrheic Dermatitis, PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC3579488/)
14. [Clinical efficacies of shampoos containing ciclopirox olamine (1.5%) and ketoconazole (2.0%) in the treatment of seborrhoeic dermatitis, PubMed](https://pubmed.ncbi.nlm.nih.gov/17520465/)
15. [Seborrhoeic dermatitis of the scalp, BMJ Clinical Evidence, PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC4445675/)
16. [More yeast, more problems?: reevaluating the role of Malassezia in seborrheic dermatitis, PubMed (2024)](https://pubmed.ncbi.nlm.nih.gov/38472524/)
17. [Wikramanayake et al. (2019). Seborrheic dermatitis—Looking beyond Malassezia. Experimental Dermatology](https://onlinelibrary.wiley.com/doi/10.1111/exd.14006)
18. [A comprehensive literature review and an international expert consensus on the management of scalp seborrheic dermatitis in adults, PubMed (2024)](https://pubmed.ncbi.nlm.nih.gov/38919137/)
---
*Topic: Encyclopedia › Life and health › Human health and medicine › Diseases and injuries › Skin and musculoskeletal conditions › Inflammatory dermatoses › Dermatitis and eczema › Dermatitis*
*Initially written Oct 21, 2026*
*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*
License: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license